The FY2025 (Dec) proxy of Ardelyx names 19 peer companies for pay. Among Ardelyx and these peers, CEO pay was 6th highest of 11 and total shareholder return was 9th highest of 11.
6th highest of 11in Ardelyx and its pay peers, FY2025 (Dec) by CEO pay:
$1.7M$35.9M
9th highest of 11in Ardelyx and its pay peers, FY2025 (Dec) by total shareholder return:
$57$495
Pay peer group, FY2025 (Dec) proxy
| Ocular Therapeutix | ||
| TG Therapeutics | ||
| Mirum Pharmaceuticals | ||
| Adma Biologics | ||
| Travere Therapeutics | ||
| Arcutis Biotherapeutics | ||
| Tarsus Pharmaceuticals | ||
| Evolus | ||
| Innoviva | ||
| Collegium Pharmaceutical | ||
| Amicus Therapeutics, Inc. | Not disclosed | Not disclosed |
| Biocryst Pharmaceuticals | Not disclosed | Not disclosed |
| Catalyst Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Dynavax Technologies Corporation | Not disclosed | Not disclosed |
| Ironwood Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Mannkind | Not disclosed | Not disclosed |
| Rhythm Pharmaceuticals | Not disclosed | Not disclosed |
| Vericel | Not disclosed | Not disclosed |
| Xencor | Not disclosed | Not disclosed |
19 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.